Guggenheim initiates Faeth Therapeutics at Buy; $70 price target
Benzinga reports Guggenheim initiated Faeth Therapeutics (FTH) with a Buy rating and a $70.00/share price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.